Indian J Pharm Close
 

Table 13: Question 4 (iii): In a post‑menopausal patient with HR +ve/Her2 – ve breast cancer who has progressed on exemestane and who is a candidate for further endocrine therapy what would you consider as the most appropriate line of therapy?

Table 13: Question 4 (iii): In a post‑menopausal patient with HR +ve/Her2 – ve breast cancer who has
progressed on exemestane and who is a candidate for further endocrine therapy what would you consider
as the most appropriate line of therapy?